Genmab A/S
GMAB
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivaā¦ read more
Healthcare
Biotechnology
17 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$28.87
Price+0.80%
$0.23
1Y
Price
Market Cap
$17.724b
Large
Price/Earnings 3y Avg5y Avg
20.8x
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+20.8%
EBITDA Margin+5.9%
Net Profit Margin-0.2%
Free Cash Flow Margin+20.8%
EBITDA Margin+5.9%
Net Profit Margin-0.2%
Free Cash Flow MarginRevenue
$3.901b
+4.8%
1y CAGR-15.7%
3y CAGR-8.4%
5y CAGREarnings
$821.033m
-14.8%
1y CAGR-7.4%
3y CAGR-10.6%
5y CAGREPS
$1.32
-14.3%
1y CAGR-5.9%
3y CAGR-9.4%
5y CAGRBook Value
$5.682b
$12.376b
Assets$6.694b
Liabilities$5.351b
DebtDebt to Assets
43.2%
4.3x
Debt to EBITDAFree Cash Flow
$871.334m
-24.2%
1y CAGR-33.6%
3y CAGR-1.5%
5y CAGRNo items found.
Press Releases
Statements and updates from the company